Business Wire

IWBI Launches Global Network of Advisors for WELL Portfolio

Share

The International WELL Building Institute™ (IWBI™) today announced the formation of a global advisory to help shape and advance the implementation of the WELL Portfolio™ Pathway pilot, a new streamlined pathway for WELL Certification™ for multiple new or existing buildings and tenant spaces in a single portfolio.

WELL Portfolio, announced this past month, is being released as part of the WELL v2™ pilot, the latest iteration of the WELL Building Standard™ (WELL™). It is part of a suite of enhancements to WELL that addresses growing demand across the building industry for a program that helps owners, developers and tenants streamline and scale health and wellness upgrades to their real estate assets. The advisory includes a collection of professionals, practitioners and experts across a range of industries and sectors, each serving a one-year term.

“Since we launched WELL, we’ve seen an explosion of interest from global companies to bring the same health and wellness benefits across their portfolios,” said IWBI Chairman and CEO Rick Fedrizzi. “The commitment of our early adopters who are now sharing their knowledge in this advisory role is what will make this process work efficiently for more companies and positively impact more people in every corner of the globe.”

Last month, IWBI announced the pilot participants, which include Barclays, Brandywine Realty Trust, CBRE Global Investors and CBRE, Charter Hall, Forest City Realty Trust, Gro, Investa, JLL Asia Pacific, the Lendlease managed Australian Prime Property Fund (APPF) Commercial, Milliken, Miron Construction Co., Inc., Prologis, Inc., Shaw Industries, and SL Green Realty Corp.

Earlier this year, IWBI named its concept advisories, a network of professionals to help explore, better understand and, ultimately, more accurately quantify the impact of specific health intents captured in the 10 WELL Concepts – Air, Water, Nourishment, Light, Movement, Thermal Comfort, Materials, Sound, Mind and Community.

“When we launched WELL v2, we recognized that when it comes to human health, we can never stop learning,” Fedrizzi added. “By listening to our knowledgeable and committed community of thought leaders and experts, we have taken another step forward in our journey to advance human health in buildings.”

The WELL Portfolio Advisory includes:

Rahul Agrawal, Head of Workplace Strategy, Planning and Projects, BNP Paribas (New York, NY); Jennifer Berthelot-Jelovic, President and CEO, A SustainAble Production, LLC (ASAP) (Los Angeles, CA); Frances Cabrera, Operational Governance Manager, VP, CRES and Location Strategy, Barclays (New York NY); Matthew Clifford, Head of Energy and Sustainability Services, JLL Asia Pacific (Australia); Andrew Cole, General Manager Sustainability, Investment Management, Lendlease (Australia); Tim Conway, VP Sustainability, Shaw Industries (Columbus, OH); Duane Desiderio (Washington, D.C.); Jessica Elengical, Head of ESG Strategy, Alternatives, DWS Group (New York, NY); Billy Grayson, Executive Director, Center for Sustainability and Economic Performance, Urban Land Institute (Washington, D.C.); Alex Grella, General Manager of University City, Brandywine Realty Trust (Philadelphia, PA); Tim Habraken, Associate Director Sustainability, CBRE (Amsterdam, Netherlands); Tom Hicks, Founding Principal and Managing Director, The Mabus Group (Washington, D.C.); Philip Ivey, Global Strategic Sustainability Leader, Milliken’s Global Floor Covering Division (Atlanta, Georgia); Nina James, General Manager, Corporate Sustainability, Investa (Australia); Theresa Lehman, Director of Sustainable Services, Miron Construction (Neenah, WI); John Mandyck, CEO, Urban Green Council (New York, NY); Kelly McCarthy, Director, IRIS, Impact Measurement & Management, Global Impact Investing Network (GIIN) (New York, NY); Joyce Mihalik, VP Design Services, Forest City Realty Trust (Cleveland, OH); Chris Moriarty, Director of Insight, British Institute of Facilities Management (BIFM) (United Kingdom); Lara Muller, CEO, Blue Building Institute (BBI), (The Hague, Netherlands); Ryan Picarella, CEO, Wellness Council of America (WELCOA) (Omaha, NE); Oliver Pye, Associate Director, Evora Global (United Kingdom); Tony Short, Workplace Project Manager, Charter Hall (Australia); Grant Stevens, Managing Director, Global Construction Management and Development, Prologis, Inc (Denver, CO); Laura Vulaj, Senior Vice President and Director of Sustainability for SL Green (New York, NY); Dick Watson, Director, Wellbeing Operations, Aetna (Hartford, CT)

About IWBI and WELL

The International WELL Building Institute™ (IWBI™) is leading the global movement to transform our buildings and communities in ways that help people thrive. The WELL v2™ pilot is a recently launched version of its popular WELL Building Standard™ (WELL™), which will continue to be offered to the market, along with the WELL Community Standard™ pilot, a district scale rating system that sets a new global benchmark for healthy communities. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. IWBI convenes and mobilizes the wellness real estate community through management of the WELL AP™ credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellness everywhere. For more information about IWBI and WELL, please visit us here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
International WELL Building Institute
Jamie Matos
jamie.matos@wellcertified.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

HiddenA line styled icon from Orion Icon Library.Eye